Natalizumab
| العنوان: | Natalizumab |
|---|---|
| المؤلفون: | Babaesfahani A; Ross University, Kern Medical Center, Khanna NR; California Northstate University, Kuns B; Ohio University Heritage College of OM |
| المصدر: | 2022 Jan. |
| المصدر: | In: StatPearls |
| نوع المنشور: | Study Guide |
| اللغة: | English |
| بيانات الدورية: | Publisher: StatPearls Publishing Cited Medium: Internet |
| أسماء مطبوعة: | Treasure Island (FL) : StatPearls Publishing |
| مستخلص: | Natalizumab is an FDA-approved monoclonal antibody approved for the treatment of multiple sclerosis and Crohn's disease. The drug was originally approved to treat multiple sclerosis in 2004, but after reported cases of death due to progressive multifocal leukoencephalopathy during treatment with natalizumab, the FDA removed the drug from the market. However, in 2006, the FDA reintroduced the drug when multiple protests by those with multiple sclerosis advocated for the use of natalizumab in conjunction with the establishment of an advisory committee that would monitor those on natalizumab. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, monitoring, and toxicity of natalizumab so that providers can direct patient therapy to optimal outcomes for MS patients. (Copyright © 2022, StatPearls Publishing LLC.) |
| References: | Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med. 2017 Jun;65(5):883-891. (PMID: 28130412) Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005 Jul 28;353(4):369-74. (PMID: 15947079) Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar;8(3):254-60. (PMID: 19201654) Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci. 2010 May 15;292(1-2):28-35. (PMID: 20236661) Lu ZY, Chen WC, Li YH, Li L, Zhang H, Pang Y, Xiao ZF, Xiao HW, Xiao Y. TNF-α enhances vascular cell adhesion molecule-1 expression in human bone marrow mesenchymal stem cells via the NF-κB, ERK and JNK signaling pathways. Mol Med Rep. 2016 Jul;14(1):643-8. (PMID: PMC491861727221006) Kanwar JR, Kanwar RK, Wang D, Krissansen GW. Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunol Cell Biol. 2000 Dec;78(6):641-5. (PMID: 11114975) Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005 Apr 26;64(8):1336-42. (PMID: 15851719) Gerardi C, Bertele' V, Rossi S, Garattini S, Banzi R. Preapproval and postapproval evidence on drugs for multiple sclerosis. Neurology. 2018 May 22;90(21):964-973. (PMID: 29695598) Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Apr 24;90(17):777-788. (PMID: 29686116) Drugs and Lactation Database (LactMed) [Internet] National Library of Medicine (US); Bethesda (MD): 2022. May 15, Natalizumab. (PMID: 0) Stüve O, Hemmer B. The genetics of natalizumab hypersensitivity: One learns to itch where one can scratch. Neurol Neuroimmunol Neuroinflamm. 2014 Dec;1(4):e52. (PMID: PMC426803425520959) Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017 Nov;16(11):925-933. (PMID: 28969984) Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 May 17;366(20):1870-80. (PMID: 22591293) Gasim M, Bernstein CN, Graff LA, Patten SB, El-Gabalawy R, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Marrie RA, CIHR team “Defining the burden and managing the effects of psychiatric comorbidity in chronic inflammatory disease” Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. Mult Scler Relat Disord. 2018 Nov;26:124-156. (PMID: 30248593) Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 Mar 02;354(9):924-33. (PMID: PMC193451116510746) |
| تواريخ الأحداث: | Date Created: 20220422 |
| رمز التحديث: | 20240629 |
| PMID: | 30480940 |
| Book AN: | NBK534201 |
| قاعدة البيانات: | MEDLINE |
| الوصف غير متاح. |